Note: EPS may not be comparable

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q4 EPS of ($0.56), $0.02 worse than the analyst estimate of ($0.54).

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.